These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The long-term treatment of patients with benign prostatic hyperplasia using Proscar].
    Author: Lopatkin NA, Roilans PJ, Stoner E.
    Journal: Urol Nefrol (Mosk); 1996; (1):2-4. PubMed ID: 8659035.
    Abstract:
    The drug proskar (finasterid) has been developed and synthetized in "Merck Sharp & Dohme" research laboratories and tried initially in healthy male volunteers. Proskar is highly active as a blocker of 5-alpha-reductase blocking conversion of testosteron in dehydrotestosteron (DHT). The assessment of proskar effect on the prostate has been performed in 2000 patients throughout the world, including Russia. Follow-up studies (up to 5 years) demonstrate that proskar in the dose 5 mg/day produces a reduction in the levels of specific prostatic antigen, serum DHT and prostatic size, an increase in urination rate, life quality. In benign prostatic hyperplasia proskar realizes its effect in hormonal nature of the disease. The advantages are also safety and rare occurrence of side effects. The response became noticeable on the treatment month 6.
    [Abstract] [Full Text] [Related] [New Search]